Cochrane Review: Antenatal magnesium sulphate reduces cerebral palsy after preterm birth, implementation into clinical practice needs to be accelerated globally to benefit preterm babies

Zusammenfassung

Antenatal magnesium sulphate reduces cerebral palsy after preterm birth, implementation into clinical practice needs to be accelerated globally to benefit preterm babies | Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in About Cookies . I ac

Kerninformationen

er content. Sections without translation will be in English. Deutsch English Español فارسی Français हिन्दी Hrvatski Bahasa Indonesia 日本語 한국어 Magyar Bahasa Malaysia Nederlands Polski Português Русский Română தமிழ் ภาษาไทย 繁體中文 简体中文 Website language Select your preferred language for the Cochrane Libr...

ks, cerebral palsy prevalence is respectively 1.2 per 1000, 4.2 per 1000, 32.4 per 1000 and 70.6 per 1000 live births [ 2 ] . The first women were enrolled in trials that evaluated magnesium sulphate for fetal neuroprotection from 1995, and the first Cochrane review, published in 2009, concluded tha...

monstrated that in subgroup analysis the number needed to treat to prevent one case of cerebral palsy was 31 at gestations of under 28 weeks, 66 at 28 to 31 weeks and 90 at over 32 weeks [ 6 ] . Magnesium sulphate use for fetal neuroprotection below 30 weeks’ gestation increased between 2012 and 201...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen